InterVenn Biosciences, a South San Francisco, Calif.-based company that utilizes a proprietary glycoproteomics biomarker interrogation platform using AI and mass spectrometry for next-gen precision medicine, completed a $201m Series C financing.
The round was led by new investors SoftBank Group, Heritage Provider Network, Irving Investors, Highside Capital Management, and backed by existing investors Amplify Partners, Anzu Partners, Genoa Ventures and True Ventures.
The company intends to use the funds to accelerate development and commercialization of Dawn™, a liquid biopsy assay for immune checkpoint inhibitor response prediction, and to expand the network of partners on its AI-driven glycoproteomics platform to accelerate development and commercialization of new clinical solutions, and broaden insights into new biomarkers and therapies.
Led by Aldo Carrascoso, Co-Founder and Chief Executive Officer, InterVenn Biosciences utilizes a proprietary glycoproteomics biomarker interrogation platform using AI and mass spectrometry for next-gen precision medicine. The company is working to find new solutions in ovarian, pancreatic, liver, prostate, and kidney cancer, together with solutions for treatment and monitoring, immune profiling, patient stratification, and disease progression.
To date, the InterVenn glycoproteomics platform has been used to develop 16 clinical use cases across oncology and other indications. Dawn™ is currently under development and is planned to be commercialized in 2022. The company will invest in the development of glycoproteomics-based liquid biopsy solutions across the oncology spectrum of care (screening through therapy response monitoring), as well as non-oncology applications.
FinSMEs
02/08/2021